Spots Global Cancer Trial Database for renal impairment
Every month we try and update this database with for renal impairment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | NCT06004661 | Metastatic Cast... | AAA617 68Ga-PSMA-11 | 18 Years - | Novartis | |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | NCT02571036 | Gastrointestina... Advanced System... Advanced Cancer... | DCC-2618 DCC-2618 | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Bortezomib-Dexamethasone-Doxorubicin-Study | NCT00401804 | Multiple Myelom... Renal Insuficie... | Dexamethasone, ... | 18 Years - | Austrian Forum Against Cancer | |
| Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors | NCT02303015 | Germ Cell Cance... | 15 Years - | Rigshospitalet, Denmark | ||
| Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases | NCT00434447 | Bone Neoplasms | Zoledronic acid | 18 Years - | Novartis | |
| Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors | NCT02303015 | Germ Cell Cance... | 15 Years - | Rigshospitalet, Denmark | ||
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | NCT05147493 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Bortezomib Cyclophosphamid... Dexamethasone Lenalidomide | 18 Years - | Hellenic Society of Hematology | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| Renal Hypothermia During Partial Nephrectomy | NCT01529658 | Renal Impairmen... Kidney Diseases Urologic Diseas... Cancer Hypothermia Kidney Cancer | Renal hypotherm... | 18 Years - | Ottawa Hospital Research Institute | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy | NCT06408597 | Prostate Cancer Bladder Cancer Surgery Renal Impairmen... Renal Injury, A... | Nitroglycerin I... Mannitol Infusi... Fluid Regimen | 18 Years - 70 Years | Cairo University | |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | NCT05298683 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Pomalidomide Dexamethasone Acetaminophen (... Ranitidine (or ... Diphenhydramine... | 18 Years - | Hellenic Society of Hematology | |
| Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | NCT00652626 | MDS AML Solid Tumors Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... | azacitidine | 18 Years - | Celgene | |
| Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | NCT00652626 | MDS AML Solid Tumors Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... | azacitidine | 18 Years - | Celgene | |
| Study of Copanlisib in Hepatic or Renal Impairment | NCT03172884 | Hepatic Insuffi... | Copanlisib (ALI... | 18 Years - 80 Years | Bayer | |
| Bortezomib-Dexamethasone-Doxorubicin-Study | NCT00401804 | Multiple Myelom... Renal Insuficie... | Dexamethasone, ... | 18 Years - | Austrian Forum Against Cancer | |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment | NCT02301117 | Advanced Solid ... | TAS-102 | 18 Years - | Taiho Oncology, Inc. | |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | NCT02571036 | Gastrointestina... Advanced System... Advanced Cancer... | DCC-2618 DCC-2618 | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Renal Hypothermia During Partial Nephrectomy | NCT01529658 | Renal Impairmen... Kidney Diseases Urologic Diseas... Cancer Hypothermia Kidney Cancer | Renal hypotherm... | 18 Years - | Ottawa Hospital Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
